𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Response of ovarian carcinomas to gefitinib–carboplatin–paclitaxel combination is not associated with EGFR kinase domain somatic mutations

✍ Scribed by Ludovic Lacroix; Patricia Pautier; Pierre Duvillard; Nelly Motté; Patrick Saulnier; Jean-Michel Bidart; Jean-Charles Soria


Book ID
102275559
Publisher
John Wiley and Sons
Year
2005
Tongue
French
Weight
51 KB
Volume
118
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Recent reports suggest that mutations in the epidermal growth factor receptor (EGFR) predict sensitivity to EGFR kinase inhibitors. 1,2 Patients with lung cancer (70-100%) har